Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

T CELL SCIENCES' FIRST DRUG R&D AGREEMENT IS WITH PFIZER

Executive Summary

T CELL SCIENCES' FIRST DRUG R&D AGREEMENT IS WITH PFIZER covering the development of products for the treatment of rheumatoid arthritis and type I diabetes, the company announced in a Sept. 2 press release. Under the terms of the deal, Pfizer will provide $4.5-$7 mil. over three years for product research and development activities based upon T Cell Sciences' proprietary antigen receptor technology. In return for funding R&D in this area, Pfizer will receive exclusive, worldwide right to market any products resulting from the collaboration. T Cell Sciences will receive royalties on sales and, in addition, retain exclusive rights to all diagnostic products that may come out of this research. "This collaboration marks a major step for T Cell Sciences, in that it supplies the financial commitment necessary for us to apply our technology to the promising area of immunoregulatory therapy," said Stephen Chubb, president of Cambridge, Massachusetts-based T Cell Sciences. The agreement with Pfizer is the second for T Cell with a major drug company. Approximately three months ago, the firm entered into a $6 mil., four-year deal with Syntex covering diagnostic products in the infectious disease and cancer areas. Under that agreement, T Cell will contribute 25%, or $1.5 mil., and have co-marketing rights with Syntex. Initially, research efforts will focus on cytomegalovirus. Chief among T Cell Sciences' five currently marketed products is the Cell Free test kit, which quantitatively measures the interleukin-2 receptor in serum. Having completed its first public offering last May, the company said it expects to generate roughly $1 mil. in product revenues for the fiscal year ending April 30, 1987.

You may also be interested in...



Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth

UsernamePublicRestriction

Register

LL1126093

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel